Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 3:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–4 of 4 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: K-321 Solution Clear all
Completed Phase 3 Interventional

A Study to Investigate the Safety and Efficacy of K-321 Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)

NCT05826353
View directory record Official record
Conditions
Fuchs Endothelial Corneal Dystrophy
Interventions
Ripasudil, Placebo
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
21
States / cities
Los Angeles, California • Palo Alto, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 7, 2026, 3:59 PM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Cataract Surgery

NCT05528172
View directory record Official record
Conditions
Corneal Edema After Cataract Surgery
Interventions
Ripasudil, Placebo
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
44
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Hemet, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 7, 2026, 3:59 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)

NCT05795699
View directory record Official record
Conditions
Fuchs Endothelial Corneal Dystrophy
Interventions
Ripasudil, Placebo
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
26
States / cities
Los Angeles, California • Palo Alto, California • Sacramento, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Sep 7, 2026, 3:59 PM EDT
Completed Phase 2 Interventional Results available

Study to Investigate the Safety and Efficacy of K-321 in Patients With Fuchs Endothelial Corneal Dystrophy (FECD) Following Descemetorhexis

NCT04250207
View directory record Official record
Conditions
Fuchs' Endothelial Corneal Dystrophy
Interventions
K-321 Solution, Placebo Solution
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
19
States / cities
Los Angeles, California • Palo Alto, California • Sacramento, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Sep 7, 2026, 3:59 PM EDT